Multiple Sclerosis Clinical Trials
Sutter Health participates in clinical trials related to Multiple Sclerosis throughout their Northern California facilities. See the listing below for an overview of current trials, including contact information. For some trials, more detailed information can be found via the title link to ClinicalTrials.gov.
Title: A 12-Month, prospective, randomized, active-controlled, open-label study to evaluate the patient retention of fingolimod vs. approved first-line disease modifying therapies (DMT) in adult who are in early stages of treatment for relapsing remitting multiple sclerosis (RRMS).
Description: To evaluate the effectiveness of fingolimod 0.50 mg/day versus approved first line disease modifying therapies (DMT) as measured by patient retention on randomized treatment over 12 months.
Investigator: William Au, MD
Eligibility: Patients age 18 to 65 inclusive with RRMS, EDSS score of less or equal to 6 inclusive at screening visit, naïve to treatment or who have been treated with no more than one class of DMT previously and women of childbearing potential must have a negative serum and urine pregnancy test at screening and baseline.
Status: Pending start up
Location: Sutter Medical Center, Sacramento
Contact: A. Linh Dang-Chu, CCRP (916) 733-4482, DangAL1@sutterhealth.org
Title: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneoulsy once daily in patients with relapsing-remitting multiple sclerosis (RRMS)
Description: To compare 2 doses (0.25 mg and 0.50 mg) of fingolimod to copaxone (20mg) and to evaluate the efficacy of fingolimod 0.25 mg for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) as part of a post approval commitment for the FDA.
Investigator: William Au, MD
Eligibility: Patients age 18 to 65 inclusive with RRMS, EDSS score of 0 to 6 inclusive at screening visit.
Status: Active and open to enrollment
Location: Sutter Medical Center, Sacramento
Contact: A. Linh Dang-Chu, CCRP (916) 733-4482,DangAL1@sutterhealth.org
Title: A Phase II, Randomized, Double-Blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults with Relapsing-remitting Multiple Sclerosis (National Institute of Allergy and Infectious Diseases) Opens in a new window 
Description: The ACCLAIM study is testing whether the medication "abatacept" can be of benefit to patients with relapsing-remitting multiple sclerosis. Although abatacept is an investigational medication for MS, it is not a new drug - it has been approved by the FDA to treat rheumatoid arthritis.
Investigator: Joanna Cooper, MD
Eligibility:
Status: Active and open to enrollment
Location: Alta Bates Summit Medical Center
Contact: Bethany Wexler
510 204-1608 Email: WexlerB@sutterhealth.org
Title: A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects with Spasticity due to Multiple Sclerosis (XenoPort, Inc.)Opens in a new window
Description: To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).
Investigator: Joanna Cooper, MD
Eligibility: Multiple sclerosis.
Status: Active and open to enrollment
Location: Alta Bates Summit Medical Center
Contact: Jody Dosanjh 510 204-1610 Email: dosanjp@sutterhealth.org
Title: A Phase 2, Double-Blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis (Avanir Pharmaceuticals)Opens in a new window
Description: The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses of AVP-923 capsules in the treatment of central neuropathic pain in patients with multiple sclerosis.
Investigator: Joanna Cooper, MD
Eligibility: Multiple sclerosis.
Status: Active and open to enrollment
Location: Alta Bates Summit Medical Center
Contact: Jody Dosanjh 510 204-1610 Email: dosanjp@sutterhealth.org
Title: A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients.
Description: The primary purpose of this study is to determine which baseline and yearly response factors predict the clinical disease-free status response in subsequent years. The study will also clarify the effectiveness of Tysabri at establishing and maintainging this overall disease-free state.
Investigator: Joanna Cooper, MD
Eligibility: Patients age 18 to 45 with a diagnosis of Relapsing Multiple Sclerosis who test negative for the Anti-JCV antibodyand are treatment-naïve to disease-modifying therapyand approved to use Tysabri.
Status: Active and open to enrollment
Location: Alta Bates Summit Medical Center
Contact: Bethany Wexler 510-204-1608 Email: WexlerB@sutterhealth.org
Title: A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects with Secondary Progressive Multiple Sclerosis.
Description: The study will assess the efficacy and safety of Tcelna compared to placebo in subjects with Secondary Progressive Multiple Sclerosis.
Investigator: Joanna Cooper, MD.
Status: Active and open to enrollment
Location: Alta Bates Summit Medical Center
Contact: Bethany Wexler 510-204-1608 Email: WexlerB@sutterhealth.org
> See All Neurology Clinical Trials by Condition